{"id":4029,"date":"2020-09-03T12:38:00","date_gmt":"2020-09-03T16:38:00","guid":{"rendered":"https:\/\/www.localresultsnow.com\/research\/?p=4029"},"modified":"2026-01-09T12:42:37","modified_gmt":"2026-01-09T17:42:37","slug":"prelude-therapeutics-gets-50m-series-c-funding","status":"publish","type":"post","link":"https:\/\/www.localresultsnow.com\/research\/prelude-therapeutics-gets-50m-series-c-funding\/","title":{"rendered":"Prelude Therapeutics gets $50M Series C funding"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"4029\" class=\"elementor elementor-4029\">\n\t\t\t\t<div class=\"elementor-element elementor-element-698e8a5 e-flex e-con-boxed e-con e-parent\" data-id=\"698e8a5\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-06d725e elementor-widget elementor-widget-image\" data-id=\"06d725e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t<figure class=\"wp-caption\">\n\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" src=\"https:\/\/delawarebusinesstimes.com\/wp-content\/uploads\/2024\/03\/kris-vaddi-prelude-therapeutics-delaware-biotech-e1585257803703-4d0124cb.jpg.webp\" title=\"Prelude Therapeutics gets $50M Series C funding\" alt=\"Kris Vaddi Prelude Therapeutics Delaware Biotech E1585257803703 4d0124cb.jpg\" loading=\"lazy\" \/>\t\t\t\t\t\t\t\t\t\t\t<figcaption class=\"widget-image-caption wp-caption-text\">Prelude Therapeutics, led by CEO Kris Vaddi, recently closed its third funding round. | PHOTO COURTESY OF PRELUDE THERAPEUTICS<\/figcaption>\n\t\t\t\t\t\t\t\t\t\t<\/figure>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-34c0f65 elementor-widget elementor-widget-heading\" data-id=\"34c0f65\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\"><span style=\"white-space: normal;font-size: 48px;font-weight: 700\">Prelude Therapeutics gets $50M Series C funding<\/span><\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-f1d9e90 elementor-widget elementor-widget-text-editor\" data-id=\"f1d9e90\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h3>WILMINGTON \u2013 Prelude Therapeutics, a private life sciences start-up company, announced Aug. 24 that it has closed a $50 million Series C financing round, continuing its explosive growth in only four years.<\/h3><h3>The new funds come from Prelude\u2019s two existing institutional investors, including New York-based OrbiMed Advisors LLC, and a new investor, Boston-based Fidelity Management &amp; Research Company LLC. When combined with its previous investment rounds, it has secured a total investment of $145 million after starting with $5 million in start-up funds.<\/h3><h3>\u00a0<\/h3><p><span style=\"text-decoration: underline;\"><a href=\"https:\/\/delawarebusinesstimes.com\/news\/prelude-series-c\/?utm_campaign=Newsletter%20-%20DBT%20-%20News&amp;utm_medium=email&amp;_hsmi=93923613&amp;_hsenc=p2ANqtz-8chc8v48CKXmZfz8QvJks74iEiW0YtgB9IT40ZofR7lGDU5A0mZc_6j3G7PDxk4PeOUkak69x1TP2JLNn8Dif_VJkKCg&amp;utm_content=93923613&amp;utm_source=hs_email\" target=\"_blank\" rel=\"noopener\">Click here to the the full Delaware Business Times article.<\/a><\/span><\/p><footer class=\"entry-footer\"><h3 class=\"entry-meta\">\u00a0<\/h3><\/footer>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d14d5dc elementor-widget elementor-widget-spacer\" data-id=\"d14d5dc\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>WILMINGTON \u2013 Prelude Therapeutics, a private life sciences start-up company, announced Aug. 24 that it has closed a $50 million Series C financing round, continuing its explosive growth in only four years.<\/p>\n<p>The new funds come from Prelude\u2019s two existing institutional investors, including New York-based OrbiMed Advisors LLC, and a new investor, Boston-based Fidelity Management &#038; Research Company LLC. When combined with its previous investment rounds, <\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_angie_page":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"page_builder":"","footnotes":""},"categories":[1],"tags":[],"class_list":["post-4029","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/www.localresultsnow.com\/research\/wp-json\/wp\/v2\/posts\/4029","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.localresultsnow.com\/research\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.localresultsnow.com\/research\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.localresultsnow.com\/research\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.localresultsnow.com\/research\/wp-json\/wp\/v2\/comments?post=4029"}],"version-history":[{"count":4,"href":"https:\/\/www.localresultsnow.com\/research\/wp-json\/wp\/v2\/posts\/4029\/revisions"}],"predecessor-version":[{"id":4033,"href":"https:\/\/www.localresultsnow.com\/research\/wp-json\/wp\/v2\/posts\/4029\/revisions\/4033"}],"wp:attachment":[{"href":"https:\/\/www.localresultsnow.com\/research\/wp-json\/wp\/v2\/media?parent=4029"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.localresultsnow.com\/research\/wp-json\/wp\/v2\/categories?post=4029"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.localresultsnow.com\/research\/wp-json\/wp\/v2\/tags?post=4029"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}